Phase I study of RO7673396, a RAS pathway inhibitor in advanced tumors

This study evaluates the safety and preliminary anti-tumor activity of RO7673396 in patients with advanced solid tumors harboring RAS mutations. In Stage 1, patients receive escalating doses to determine the recommended level, followed by Stage 2 where the defined dose is used until progression or toxicity. The trial, sponsored by Hoffmann-La Roche, focuses on RAS-targeted treatment in this specific patient population.